Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis

Stock Information for Galera Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Galera Therapeutics Inc.

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.